Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Non Operating Income (2023 - 2026)

Compass Therapeutics' Non Operating Income history spans 4 years, with the latest figure at $2.0 million for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 48.69% to $2.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.0 million, a 6.03% increase, with the full-year FY2025 number at $6.4 million, down 12.41% from a year prior.
  • Non Operating Income hit $2.0 million in Q1 2026 for Compass Therapeutics, down from $2.3 million in the prior quarter.
  • Over the last five years, Non Operating Income for CMPX hit a ceiling of $2.3 million in Q4 2025 and a floor of $1.2 million in Q2 2025.
  • Historically, Non Operating Income has averaged $1.8 million across 4 years, with a median of $2.0 million in 2023.
  • Biggest five-year swings in Non Operating Income: plummeted 39.82% in 2025 and later skyrocketed 48.69% in 2026.
  • Tracing CMPX's Non Operating Income over 4 years: stood at $2.0 million in 2023, then dropped by 22.09% to $1.5 million in 2024, then skyrocketed by 47.57% to $2.3 million in 2025, then dropped by 12.84% to $2.0 million in 2026.
  • Business Quant data shows Non Operating Income for CMPX at $2.0 million in Q1 2026, $2.3 million in Q4 2025, and $1.6 million in Q3 2025.